Your browser doesn't support javascript.
loading
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.
Escamilla, Jemima; Schokrpur, Shiruyeh; Liu, Connie; Priceman, Saul J; Moughon, Diana; Jiang, Ziyue; Pouliot, Frederic; Magyar, Clara; Sung, James L; Xu, Jingying; Deng, Gang; West, Brian L; Bollag, Gideon; Fradet, Yves; Lacombe, Louis; Jung, Michael E; Huang, Jiaoti; Wu, Lily.
Afiliação
  • Escamilla J; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Schokrpur S; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Liu C; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Priceman SJ; Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute at City of Hope, Duarte, California.
  • Moughon D; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Jiang Z; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Pouliot F; Department of Surgery, Urology Division, Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.
  • Magyar C; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Sung JL; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Xu J; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Deng G; Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, California.
  • West BL; Plexxikon Inc., Berkeley, California.
  • Bollag G; Plexxikon Inc., Berkeley, California.
  • Fradet Y; Department of Surgery, Urology Division, Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.
  • Lacombe L; Department of Surgery, Urology Division, Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.
  • Jung ME; Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, California.
  • Huang J; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Wu L; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. lwu@mednet.ucla.edu.
Cancer Res ; 75(6): 950-62, 2015 Mar 15.
Article em En | MEDLINE | ID: mdl-25736687
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Receptor de Fator Estimulador de Colônias de Macrófagos / Antagonistas de Androgênios / Macrófagos Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Receptor de Fator Estimulador de Colônias de Macrófagos / Antagonistas de Androgênios / Macrófagos Idioma: En Ano de publicação: 2015 Tipo de documento: Article